Fibrinogen for the prediction of severe maternal complications in placental abruption with fetal death after 24 weeks of gestation.
disseminated intravascular coagulation
fetal death
fibrinogen
maternal prognosis
placental abruption
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
15
07
2022
received:
03
05
2022
accepted:
09
08
2022
pubmed:
21
8
2022
medline:
15
2
2023
entrez:
20
8
2022
Statut:
ppublish
Résumé
To assess the correlation between standard laboratory indicators at admission and severe maternal complications due to placental abruption (PA) with intrauterine fetal death (IUFD) after 24 weeks. Retrospective study in three French tertiary referral hospitals. Correlation of laboratory indicators at admission (platelet count, prothrombin, activated partial thromboplastin time, fibrinogen) and severe maternal complications (massive transfusion, multiple organ failure, hysterectomy, or maternal deaths) in patients with PA and IUFD. Over 12 years, we identified 27/344 (7.8%) pregnant women presenting PA with IUFD. No patient had coagulopathy at admission. Fifteen individuals (55.5%) underwent delivery by cesarean section before or during labor. Fifteen individuals (55.5%) presented severe complications, and 17/27 (63%) lost more than 1 L of blood during delivery. Fibrinogen level was shown to be the laboratory indicator most correlated with severe complications (r = -0.52, P = 0.01). The receiver operating characteristic curve of fibrinogen less than 1.9 g/L in the prediction of severe complications (area under the curve = 0.80, 95% confidence interval [CI] 0.54-0.97) showed both a sensitivity and specificity of 83% (95% CI 54%-96%). In cases of IUFD with PA, fibrinogen levels at admission had a prognostic value for the prediction of severe maternal complications.
Identifiants
pubmed: 35986606
doi: 10.1002/ijgo.14417
pmc: PMC10087485
doi:
Substances chimiques
Fibrinogen
9001-32-5
Hemostatics
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
900-905Informations de copyright
© 2022 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.
Références
Obstet Gynecol. 2006 Oct;108(4):1005-16
pubmed: 17012465
J Obstet Gynaecol Res. 2017 Apr;43(4):676-681
pubmed: 28370793
Int J Gynaecol Obstet. 2021 Aug;154(2):343-351
pubmed: 33314186
Hypertens Pregnancy. 2001;20(2):195-203
pubmed: 12044330
Am J Obstet Gynecol. 2012 Feb;206(2):177.e1-2
pubmed: 22284157
J Med Case Rep. 2014 Dec 23;8:461
pubmed: 25532532
Int J Gynaecol Obstet. 2014 Aug;126(2):180-1
pubmed: 24745855
Blood Rev. 2015 Jan;29(1):17-24
pubmed: 25294122
Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1335-41
pubmed: 1957857
J Thromb Haemost. 2007 Feb;5(2):266-73
pubmed: 17087729
J Obstet Gynaecol Res. 2019 Jan;45(1):13-21
pubmed: 30155944
Thromb Haemost. 2009 Apr;101(4):755-61
pubmed: 19350122
Obstet Gynecol. 1954 Apr;3(4):385-93
pubmed: 13154780
Br J Anaesth. 2012 Jun;108(6):984-9
pubmed: 22490316
Emerg Radiol. 2019 Feb;26(1):87-97
pubmed: 30159815
Acta Obstet Gynecol Scand. 2011 Feb;90(2):140-9
pubmed: 21241259
Anesth Analg. 1995 Aug;81(2):360-5
pubmed: 7542432
Clin Obstet Gynecol. 1985 Mar;28(1):15-23
pubmed: 2580657
Am J Perinatol. 2017 Aug;34(10):935-957
pubmed: 28329897
Br J Haematol. 2009 Apr;145(1):24-33
pubmed: 19222477
Cochrane Database Syst Rev. 2003;(1):CD003247
pubmed: 12535464
J Thromb Haemost. 2009 Jul;7(7):1099-105
pubmed: 19422451
Int J Gynaecol Obstet. 2023 Mar;160(3):900-905
pubmed: 35986606